Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Lexaria Bioscience ( (LEXX) ) just unveiled an announcement.
Lexaria Bioscience Corp. announced the granting of two new U.S. patents for its DehydraTECH technology, specifically for treating epilepsy. These patents support Lexaria’s strategy to enhance commercial viability and provide value to pharmaceutical partners and patients, as they demonstrate improved bio-absorption and effectiveness over existing treatments like Epidiolex. The patents are part of Lexaria’s expanding intellectual property portfolio, which now includes 48 patents globally, and are set to expire in 2043.
More about Lexaria Bioscience
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms, primarily known for its patented DehydraTECH technology. This technology enhances the delivery and absorption of active pharmaceutical ingredients, particularly through oral delivery, and has been investigated with various beneficial molecules. Lexaria operates a licensed in-house research laboratory and has a strong intellectual property portfolio with 48 patents granted worldwide.
YTD Price Performance: -26.09%
Average Trading Volume: 187,890
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $31.24M
Find detailed analytics on LEXX stock on TipRanks’ Stock Analysis page.
